Heterocyclic organobismuth(III) induces apoptosis of human promyelocytic leukemic cells through activation of caspases and mitochondrial perturbation

Biochemical Pharmacology

Volumn 76, Issue 8, 2008, Pages 974-986

  Iuchi, Katsuya ^a   Hatano, Yukichi ^a   Yagura, Tatsuo ^a  

^a KWANSEI GAKUIN UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bismuth; Cell death; Glutathione; Leukemia; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BICHLORODIBENZO[C,F][1,5]THIABISMOCINE; BISMUTH DERIVATIVE; BUTHIONINE SULFOXIMINE; CASPASE 12; CASPASE 3; CASPASE 8; CASPASE 9; CATALASE; CYTOCHROME C; HETEROCYCLIC COMPOUND; HETEROCYCLIC ORGANOBISMUTH DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN HL 60; CELL STRAIN U937; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSOL; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ADENOSINE TRIPHOSPHATE; ANNEXIN A5; APOPTOSIS; BISMUTH; CASPASES; CELL SURVIVAL; DNA, NEOPLASM; HETEROCYCLIC COMPOUNDS; HL-60 CELLS; HUMANS; ORGANOMETALLIC COMPOUNDS;

EID: 52949097254     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.07.038     Document Type: Article

References (45)

1. Suzuki H., and Matano Y. Organobismuth chemistry (2001), Elsevier Science
2. Yagura T. Biological activity of organobismuth compounds. Res Adv Antimicrob Chemother 6 (2006) 19-32
3. Desoize B. Metals and metal compounds in cancer treatment. Anticancer Res 24 (2004) 1529-1544
4. Klapötke T. Biological activity of organometallic bismuth compounds. Biol Met 1 (1988) 69-76
5. Köpf-Maier P., and Klapötke T. Antitumor activity of some organometallic bismuth(III)thiolates. Inorg Chim Acta 152 (1988) 49-52
6. Tan S., Sagara Y., Liu Y., Maher P., and Schubert D. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141 (1998) 1423-1432
7. Muller I., Niethammer D., and Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1 (1998) 491-494
8. Ikeda K., Kajiwara K., Tanabe E., Tokumaru S., Kishida E., Masuzawa Y., et al. Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells. Biochem Pharmacol 57 (1999) 1361-1365
9. Kroemer G., and de Thé H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?. J Natl Cancer Inst 91 (1999) 743-745
10. Kotani T., Nagai D., Asahi K., Suzuki H., Yamao F., Kataoka N., et al. Antibacterial properties of some cyclic organobismuth(III) compounds. Antimicrob Agents Chemother 49 (2005) 2729-2734
11. Tanaka H., Takenaka H., Yamao F., and Yagura T. Aphidicolin induces alterations in Golgi complex and disorganization of microtubules of HeLa cells upon long-term administration. J Cell Physiol 176 (1998) 602-611
12. Doi K., Noma S., Yamao F., Goko H., and Yagura T. Expression of golgi membrane protein p138 is cell cycle-independent and dissociated from centrosome duplication. Cell Struct Funct 27 (2002) 117-125
13. Ganju N., and Eastman A. Bcl-X(L) and calyculin A prevent translocation of Bax to mitochondria during apoptosis. Biochem Biophys Res Commun 291 (2002) 1258-1264
14. Toescu E.C., and Verkhratsky A. Assessment of mitochondrial polarization status in living cells based on analysis of the spatial heterogeneity of rhodamine 123 fluorescence staining. Pflugers Arch 440 (2000) 941-947
15. 2 in cultured endothelial cells. Arch Biochem Biophys 302 (1993) 348-355
16. Eguchi Y., Shimizu S., and Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57 (1997) 1835-1840
17. Leist M., Single B., Castoldi A.F., Kuhnle S., and Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185 (1997) 1481-1486
18. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
19. Cryns V., and Yuan J. Proteases to die for. Genes Dev 12 (1998) 1551-1570
20. Shibata M.A., Morimoto J., Ito Y., Kusakabe K., and Otsuki Y. Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer. Med Electron Microsc 37 (2004) 216-224
21. Mehmet H. Caspases find a new place to hide. Nature 403 (2000) 29-30
22. Ferri K.F., and Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3 (2001) E255-E263
23. Nakagawa T., and Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 150 (2000) 887-894
24. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9 (2002) 459-470
25. Degterev A., Boyce M., and Yuan J. A decade of caspases. Oncogene 22 (2003) 8543-8567
26. Sohn D., Schulze-Osthoff K., and Janicke R.U. Caspase-8 can be activated by interchain proteolysis without receptor-triggered dimerization during drug-induced apoptosis. J Biol Chem 280 (2005) 5267-5273
27. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 15 (2001) 2922-2933
28. Pulido M.D., and Parrish A.R. Metal-induced apoptosis: mechanisms. Mutat Res 533 (2003) 227-241
29. Zhang T.D., Chen G.Q., Wang Z.G., Wang Z.Y., Chen S.J., and Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 20 (2001) 7146-7153
30. Huang M.J., Hsieh R.K., Lin C.P., Chang I.Y., and Liu H.J. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma 43 (2002) 2191-2199
31. Tsujimoto Y. Apoptosis and necrosis: intracellular ATP level as a determinant for cell death modes. Cell Death Differ 4 (1997) 429-434
32. Troyano A., Sancho P., Fernandez C., de Blas E., Bernardi P., and Aller P. The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death Differ 10 (2003) 889-898
33. Lennon S.V., Martin S.J., and Cotter T.G. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 24 (1991) 203-214
34. Granville D.J., Carthy C.M., Jiang H., Shore G.C., McManus B.M., and Hunt D.W. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett 437 (1998) 5-10
35. Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S.A., et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 249 (1999) 413-421
36. Slater A.F., Stefan C., Nobel I., van den Dobbelsteen D.J., and Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 82-83 (1995) 149-153
37. André N., Braguer D., Brasseur G., Gonçalves A., Lemesle-Meunier D., Guise S., et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 60 (2000) 5349-5353
38. Fan C., Li Q., Ross D., and Engelhardt J.F. Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J Biol Chem 278 (2003) 2072-2080
39. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., and Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94 (1999) 2102-2111
40. Hayashi T., Hideshima T., Akiyama M., Richardson P., Schlossman R.L., Chauhan D., et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1 (2002) 851-860
41. Zhu X.H., Shen Y.L., Jing Y.K., Cai X., Jia P.M., Huang Y., et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91 (1999) 772-778
42. Liu Q., Hilsenbeck S., and Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101 (2003) 4078-4087
43. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 (1996) 1052-1061
44. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
45. Goering P.L., Aposhian H.V., Mass M.J., Cebrian M., Beck B.D., and Waalkes M.P. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci 49 (1999) 5-14